Abreva enters new markets
This article was originally published in The Tan Sheet
Executive SummaryCold sore remedy approved for OTC sale in Canada, could be available by year end under exclusive licensing agreement with GlaxoSmithKline, Avanir Pharmaceuticals says May 28. Deal with GSK, which was announced in March 2000 and also gave GSK U.S. marketing rights to Abreva, provides Avanir with royalties based on wholesale product revenue. Before GSK launches the docosanol 10% cream in Canada, firm must attain provincial approval from the national drug scheduling recommendation committee; GSK is scheduling a presentation before committee for September. Avanir also announces product approvals in Korea, Israel...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.